Takeda/Shire Clears Last Antimonopoly Hurdle – Shareholders Up Next
Executive Summary
European Commission gives an expected conditional regulatory approval for the acquisition of Shire by Takeda, removing the last potential antitrust hurdle to the deal, meaning that attention is now turning to the upcoming shareholders' meetings that would open the final path to the early January completion of the record-setting transaction.
You may also be interested in...
Takeda Offers Shire Asset Disposal To Assuage EC Merger Concerns
Takeda may have to shed a Shire late-stage pipeline asset to meet European anti-competition concerns around the companies' planned merger, although the process is not expected to derail the deal's timing.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.
Ono, PD-1 Discoverer Settle Long-Running Patent Dispute
Japanese firm and key discoverer of immuno-oncology protein reach settlement of patent-related dispute that includes formation of new academic research fund.